Eli Lilly eyes label expansion for Omvoh after pediatric ulcerative colitis trial data shows 80% induction response rate, strengthening the drug's clinical profile.
Eli Lilly's Omvoh has demonstrated significant clinical success in a pediatric study for ulcerative colitis, with over 80% of patients achieving a response during the induction phase. By meeting the primary endpoint of clinical remission in patients aged 6 to 17, the company is now positioned to pursue global regulatory submissions to expand the drug's label beyond the current adult indication.
The study met its primary endpoint of clinical remission in patients aged 6 to 17 with ulcerative colitis.
Lilly plans to submit the clinical data to global regulators to seek approval for a pediatric label expansion.
Eli Lilly and Company announced that its drug Omvoh successfully met the primary endpoint of clinical remission in a pediatric ulcerative colitis study. With over 80% of patients showing response to induction, the company plans to seek global regulatory approval for label expansion to include patients aged 6 to 17.
The positive data allows Eli Lilly to pursue a label expansion for Omvoh, potentially broadening its market reach to include pediatric ulcerative colitis patients aged 6 to 17.